Lilly Financially Commits Additional $450M toward Research Triangle Park Facility
Expansion expected to help tackle health issues at a faster rate, company says
Eli Lilly and Company will be financing a $450 million expansion project at its manufacturing facility located in North Carolina’s Research Triangle Park. The development plan features additional parenteral filling, device assembly, and packaging capacity for incretin diabetic products. The pharma company notes that the facility is expected to generate an additional 100 manufacturing jobs upon completion in 2027.
Since 2020, Lilly has committed an estimated $4 billion to North Carolina manufacturing facilities, including $1.7 billion toward the development and growth of its aforementioned Research Triangle Park location.
“Expanding our operations at Research Triangle Park will accelerate the rate at which we can produce medicines that patients rely on to address serious health challenges like diabetes,” notes Edgardo Hernandez, EVP and president, Lilly manufacturing operations. “We're on track to achieve the goal we shared in November 2022 of doubling incretin capacity by the end of this year, but this investment is key to ensuring even more patients will have access to medicines they need in the future."
Read more about the investment here.
